Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
ICUI Transcript
ICU Medical, Inc. (ICUI) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call presents a mixed picture. While there is strong performance in IV Systems and consistent guidance for EBITDA and EPS, the decline in Vital Care revenue and management's vague responses about certain issues could cause investor uncertainty. The company's focus on reducing debt and maintaining higher price points is positive, but the lack of immediate financial impact from new hardware and unresolved issues in Vital Care tempers optimism. The market cap suggests moderate volatility, leading to a neutral prediction for the stock price movement.
ICU Medical, Inc. (ICUI) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call summary indicates solid financial performance with increased EBITDA and EPS guidance, strong cash flow, and strategic debt management. Product development is on track, with no sales impact from pending clearances. Operational improvements are expected to enhance margins, and the company is optimistic about its backlog and product refresh cycle. Although tariffs impact costs, structural mitigation efforts are underway. The Q&A reveals a stable market environment and positive analyst sentiment, with no significant risks highlighted. Given the company's market cap, these factors suggest a positive stock price movement of 2% to 8%.
ICU Medical, Inc. (ICUI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
ICU Medical, Inc. (ICUI) Q3 2025 Earnings Call Transcript
Positive11-6
The company's Q3 results show strong financial performance with improved gross margins and EPS growth. The Consumables and IV Systems segments performed well, despite challenges in the Vital Care segment. Management's cautious optimism and strategic focus on growth areas like Consumables and Systems, coupled with efforts to mitigate tariff impacts, support a positive outlook. The market cap suggests moderate volatility, leading to a predicted positive stock price movement of 2% to 8%.
ICUI Slides
ICUI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.